Anuh Pharma Past Earnings Performance
Past criteria checks 5/6
Anuh Pharma has been growing earnings at an average annual rate of 22.9%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 15.1% per year. Anuh Pharma's return on equity is 19.9%, and it has net margins of 9.3%.
Key information
22.9%
Earnings growth rate
22.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.1% |
| Return on equity | 19.9% |
| Net Margin | 9.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Anuh Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6,234 | 578 | 211 | 0 |
| 31 Mar 24 | 6,470 | 601 | 207 | 0 |
| 31 Dec 23 | 6,404 | 543 | 197 | 0 |
| 30 Sep 23 | 6,071 | 445 | 190 | 0 |
| 30 Jun 23 | 5,726 | 406 | 185 | 0 |
| 31 Mar 23 | 5,275 | 362 | 180 | 0 |
| 31 Dec 22 | 4,991 | 355 | 174 | 0 |
| 30 Sep 22 | 4,921 | 336 | 168 | 0 |
| 30 Jun 22 | 4,858 | 323 | 162 | 0 |
| 31 Mar 22 | 4,866 | 306 | 157 | 0 |
| 31 Dec 21 | 4,548 | 225 | 152 | 0 |
| 30 Sep 21 | 4,215 | 193 | 152 | 0 |
| 30 Jun 21 | 4,250 | 173 | 154 | 0 |
| 31 Mar 21 | 4,320 | 284 | 151 | 0 |
| 31 Dec 20 | 4,069 | 266 | 152 | 0 |
| 30 Sep 20 | 3,844 | 288 | 149 | 0 |
| 30 Jun 20 | 3,463 | 252 | 137 | 0 |
| 31 Mar 20 | 3,070 | 143 | 139 | 0 |
| 31 Dec 19 | 3,180 | 205 | 136 | 0 |
| 30 Sep 19 | 3,121 | 196 | 126 | 0 |
| 30 Jun 19 | 3,253 | 235 | 122 | 0 |
| 31 Mar 19 | 3,207 | 234 | 114 | 0 |
| 31 Dec 18 | 3,047 | 213 | 121 | 0 |
| 30 Sep 18 | 2,993 | 208 | 119 | 0 |
| 30 Jun 18 | 2,665 | 160 | 114 | 0 |
| 31 Mar 18 | 2,381 | 165 | 109 | 0 |
| 31 Dec 17 | 2,315 | 161 | 94 | 0 |
| 30 Sep 17 | 2,155 | 194 | 87 | 0 |
| 30 Jun 17 | 2,087 | 193 | 80 | 0 |
| 31 Mar 17 | 2,061 | 201 | 79 | 0 |
| 31 Dec 16 | 2,209 | 181 | 67 | 0 |
| 30 Sep 16 | 2,476 | 191 | 69 | 0 |
| 30 Jun 16 | 2,887 | 217 | 70 | 0 |
| 31 Mar 16 | 3,262 | 258 | 70 | 0 |
| 31 Dec 15 | 3,261 | 257 | 139 | 0 |
| 30 Sep 15 | 3,155 | 261 | 136 | 0 |
| 30 Jun 15 | 2,952 | 235 | 132 | 0 |
| 31 Mar 15 | 2,837 | 220 | 59 | 0 |
| 31 Dec 14 | 2,894 | 227 | 132 | 0 |
| 30 Sep 14 | 2,899 | 213 | 128 | 0 |
| 30 Jun 14 | 2,862 | 207 | 126 | 0 |
| 31 Mar 14 | 2,664 | 176 | 123 | 0 |
| 31 Dec 13 | 2,487 | 149 | 120 | 0 |
Quality Earnings: 506260 has high quality earnings.
Growing Profit Margin: 506260's current net profit margins (9.3%) are higher than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 506260's earnings have grown significantly by 22.9% per year over the past 5 years.
Accelerating Growth: 506260's earnings growth over the past year (42.4%) exceeds its 5-year average (22.9% per year).
Earnings vs Industry: 506260 earnings growth over the past year (42.4%) exceeded the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: 506260's Return on Equity (19.9%) is considered low.